{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:56:58Z","timestamp":1757703418750},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10549-014-2860-7","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T18:50:11Z","timestamp":1392144611000},"page":"343-351","source":"Crossref","is-referenced-by-count":12,"title":["Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study"],"prefix":"10.1007","volume":"144","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Kauka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Ziller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Birkholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Baier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Muth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,12]]},"reference":[{"key":"2860_CR1","author":"C Palmieri","year":"2013","unstructured":"Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ (2013) Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol. doi: 10.1016\/j.mce.2013.08.001","journal-title":"Mol Cell Endocrinol"},{"key":"2860_CR2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718\u20131729","journal-title":"J Clin Oncol"},{"key":"2860_CR3","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"MN Levine","year":"1998","unstructured":"Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651\u20132658","journal-title":"J Clin Oncol"},{"key":"2860_CR4","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"2860_CR5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045\u20131051","journal-title":"J Clin Oncol"},{"key":"2860_CR6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341\u20131347","journal-title":"J Clin Oncol"},{"key":"2860_CR7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","journal-title":"Lancet Oncol"},{"key":"2860_CR8","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u20134882","journal-title":"J Clin Oncol"},{"key":"2860_CR9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von MG, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398\u2013405","journal-title":"Ann Oncol"},{"key":"2860_CR10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"2860_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631\u2013641","journal-title":"Lancet Oncol"},{"key":"2860_CR12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","volume":"1092","author":"DJ Hadjidakis","year":"2006","unstructured":"Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann NY Acad Sci 1092:385\u2013396","journal-title":"Ann NY Acad Sci"},{"key":"2860_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","volume":"1192","author":"KM Nicks","year":"2010","unstructured":"Nicks KM, Fowler TW, Akel NS, Perrien DS, Suva LJ, Gaddy D (2010) Bone turnover across the menopause transition: the role of gonadal inhibins. Ann NY Acad Sci 1192:153\u2013160","journal-title":"Ann NY Acad Sci"},{"key":"2860_CR14","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1073\/pnas.88.12.5134","volume":"88","author":"R Pacifici","year":"1991","unstructured":"Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88:5134\u20135138","journal-title":"Proc Natl Acad Sci USA"},{"key":"2860_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1006289811540","volume":"56","author":"M Dowsett","year":"1999","unstructured":"Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25\u201334","journal-title":"Breast Cancer Res Treat"},{"key":"2860_CR16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bjc.1990.356","volume":"62","author":"RC Stein","year":"1990","unstructured":"Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC (1990) The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679\u2013683","journal-title":"Br J Cancer"},{"key":"2860_CR17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","volume":"90","author":"DP Forward","year":"2004","unstructured":"Forward DP, Cheung KL, Jackson L, Robertson JF (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590\u2013594","journal-title":"Br J Cancer"},{"key":"2860_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/1471-2407-13-425","volume":"13","author":"M Madeira","year":"2013","unstructured":"Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH (2013) Estrogen receptor alpha\/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer 13:425","journal-title":"BMC Cancer"},{"key":"2860_CR19","unstructured":"Fogelmann I (2001) Assessment of BMD in pre\/postmenopausal women treated with Zoladex versus CMF. Results from the ZEBRA study. St Gallen Proceedings"},{"key":"2860_CR20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2007.13.5319","volume":"26","author":"E Rossi","year":"2008","unstructured":"Rossi E, Morabito A, De ME, Di RF, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, Piccirillo MC, D\u2019Aiuto G, D\u2019Aiuto M, Rinaldo M, Botti G, Gallo C, Perrone F, de Matteis A (2008) Endocrine effects of adjuvant letrozole\u00a0+\u00a0triptorelin compared with tamoxifen\u00a0+\u00a0triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26:264\u2013270","journal-title":"J Clin Oncol"},{"key":"2860_CR21","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2008.18.6213","volume":"27","author":"E Rossi","year":"2009","unstructured":"Rossi E, Morabito A, Di RF, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De ME, Di MM, Piccirillo MC, De FG, D\u2019Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27:3192\u20133197","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2860_CR22","first-page":"50s","volume":"29","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, Jakesz R, Singer CF, Eidtmann H, Greil R (2011) Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. J Clin Oncol 29(suppl):50s","journal-title":"J Clin Oncol"},{"key":"2860_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","volume":"125","author":"JE Kim","year":"2011","unstructured":"Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY (2011) Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125:99\u2013106","journal-title":"Breast Cancer Res Treat"},{"key":"2860_CR24","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/annonc\/mds169","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Coleman R, Gnant M, Green J (2012) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 23:2782\u20132790","journal-title":"Ann Oncol"},{"key":"2860_CR25","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","volume":"24","author":"IE Smith","year":"2006","unstructured":"Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, Hayes D (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444\u20132447","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2860-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2860-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T14:38:52Z","timestamp":1565188732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2860-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,12]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2860"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2860-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,12]]}}}